NO20064200L - Fremgangsmate for syntese av en CXCR4-antagonist - Google Patents

Fremgangsmate for syntese av en CXCR4-antagonist

Info

Publication number
NO20064200L
NO20064200L NO20064200A NO20064200A NO20064200L NO 20064200 L NO20064200 L NO 20064200L NO 20064200 A NO20064200 A NO 20064200A NO 20064200 A NO20064200 A NO 20064200A NO 20064200 L NO20064200 L NO 20064200L
Authority
NO
Norway
Prior art keywords
protected
synthesis
amine
imine
reacting
Prior art date
Application number
NO20064200A
Other languages
English (en)
Inventor
Trevor R Wilson
Jason Crawford
Gang Chen
Ian Baird
Renato T Skjerlj
David Gauthier
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of NO20064200L publication Critical patent/NO20064200L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Foreliggende oppfinnelse angår fremgangsmåte for syntese av heterocykliske farmasøytiske forbindelser som bindes til CXCR4 chemokinreseptoren. I én utførelsesform, omfatter fremgangsmåten: a) omsetning av et 5,6,7,8-tetrahydrokinolinylamin og et alkylaldehyd som bærer en ftalimid eller en di-tertiær-butoksykarbonyl (di-BOC) beskyttelsesgruppe for å danne et imin; b) reduksjon av iminet for å danne et sekundært amin; c) omsetning av det sekundære aminet med en halogenalkyl substituert heterocyklisk forbindelse, for å danne et ftalimido-beskyttet eller di-tert-butoksykarbonyl beskyttet tertiær amin; og d) hydrolyse av det beskyttede aminet for å oppnå en forbindelse som har Formel I'
NO20064200A 2004-03-15 2006-09-15 Fremgangsmate for syntese av en CXCR4-antagonist NO20064200L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55358904P 2004-03-15 2004-03-15
PCT/US2005/008268 WO2005090308A1 (en) 2004-03-15 2005-03-11 Process for the synthesis of a cxcr4 antagonist

Publications (1)

Publication Number Publication Date
NO20064200L true NO20064200L (no) 2006-09-15

Family

ID=34993619

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064200A NO20064200L (no) 2004-03-15 2006-09-15 Fremgangsmate for syntese av en CXCR4-antagonist

Country Status (13)

Country Link
US (1) US7332605B2 (no)
EP (1) EP1730113B1 (no)
JP (1) JP4870660B2 (no)
KR (1) KR20060131899A (no)
CN (1) CN1930127B (no)
AU (1) AU2005224079A1 (no)
BR (1) BRPI0508703B8 (no)
CA (1) CA2558389C (no)
ES (1) ES2614508T3 (no)
IL (1) IL177511A (no)
NO (1) NO20064200L (no)
RU (1) RU2006136381A (no)
WO (1) WO2005090308A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20080045537A1 (en) * 2004-08-16 2008-02-21 Kristjan Gudmundsson Chemical Compounds
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
JP2009524689A (ja) * 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物
JP2009524690A (ja) * 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物
AU2007281090A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
WO2008134326A1 (en) * 2007-04-26 2008-11-06 Dow Global Technologies Inc. Novel aldehyde composition
FR2934859B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
CA3177537A1 (en) 2020-05-01 2021-11-04 Isaiah Arkin E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
AU2022360035A1 (en) * 2021-10-07 2024-04-18 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
JP4209472B2 (ja) * 1997-06-02 2009-01-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 平滑筋細胞増殖のインヒビターとしての（イミダゾール−５−イル）メチル−２−キノリノン誘導体
JP2003524620A (ja) 1999-03-24 2003-08-19 アノーメッド インコーポレイティド ケモカインレセプター結合複素環化合物
PL360932A1 (en) * 2000-09-15 2004-09-20 Anormed Inc. Chemokine receptor binding heterocyclic compounds
BR0113932A (pt) * 2000-09-15 2003-06-24 Anormed Inc Compostos heterocìclicos que se ligam ao receptor da quimiocina
CZ10903U1 (en) * 2001-01-11 2001-02-19 Oldrich Ing Cihak Bladed water wheel
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
JP4556020B2 (ja) * 2001-12-21 2010-10-06 ジェンザイム・コーポレーション 高い有効性を有するケモカインレセプタ結合複素環式化合物

Also Published As

Publication number Publication date
AU2005224079A1 (en) 2005-09-29
CN1930127B (zh) 2012-11-21
EP1730113A1 (en) 2006-12-13
US7332605B2 (en) 2008-02-19
ES2614508T3 (es) 2017-05-31
RU2006136381A (ru) 2008-04-27
IL177511A0 (en) 2006-12-10
KR20060131899A (ko) 2006-12-20
CA2558389A1 (en) 2005-09-29
JP2007529526A (ja) 2007-10-25
EP1730113A4 (en) 2009-12-02
US20050209277A1 (en) 2005-09-22
EP1730113B1 (en) 2016-12-28
BRPI0508703B8 (pt) 2021-05-25
CN1930127A (zh) 2007-03-14
IL177511A (en) 2010-12-30
JP4870660B2 (ja) 2012-02-08
WO2005090308A1 (en) 2005-09-29
BRPI0508703B1 (pt) 2020-11-24
CA2558389C (en) 2013-10-08
BRPI0508703A (pt) 2007-08-07

Similar Documents

Publication Publication Date Title
NO20064200L (no) Fremgangsmate for syntese av en CXCR4-antagonist
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
NO341631B1 (no) Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger
BRPI0519597A2 (pt) derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
NO20076554L (no) Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
WO2008007113A3 (en) Pharmaceutical combinations
MX2007009282A (es) Nuevos procesos para la preparacion de un 2h-cromeno.
DE60235396D1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20064175L (no) Heterosyklisk forbindelse
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
DE502006008710D1 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister
TW200606154A (en) Mercaptoimidazoles as CCR2 receptor antagonists
ATE550326T1 (de) Als modulatoren von hdl einsetzbare verbindungen
TW200606155A (en) Mercaptoimidazoles as CCR2 receptor antagonists
NO20081529L (no) Naftyridinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application